This article provides a comprehensive overview of The New Ireland Fund, Inc. (IRL) dividend history, including past payout dates, amounts, and yields. It details the latest dividend payout of $0.2003 per share on December 22, 2022, with a 2.14% dividend yield, and lists historical dividend data since 2015. The article also addresses common FAQs regarding IRL's dividend policy.

Zimmer Biomet Holdings, Inc. announced that its management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8th. A fireside chat will be held at 10:40 a.m. ET, with a live audio webcast and replay available on Zimmer Biomet's Investor Relations website.

Zimmer Biomet (NYSE:ZBH) announced its management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, featuring a fireside chat at 10:40 a.m. ET. A live audio webcast and replay will be available on the company’s investor relations website. This follows recent strong Q1 2026 results and capital allocation updates, including a quarterly dividend and increased share repurchase expectations, despite a previous stock decline coinciding with a CFO transition.

GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698) announced its 2026 Annual General Meeting will be held on June 25, 2026, at 4:00 p.m. China Standard Time in Pudong, Shanghai. Shareholders of record on June 4, 2026, including beneficial owners of American Depositary Shares (ADSs) who instruct JPMorgan, are eligible to vote. The company also confirmed the filing of its 2025 Form 20-F and Hong Kong annual report, accessible on its investor relations website, SEC, and HKEX.

Tissue Dynamics and Galmed Pharmaceuticals have identified a previously unrecognized metabolic pathway responsible for cardiac fibrosis and heart failure using a human cardiac organoid model. Their preclinical study demonstrated that a combination of Aramchol Meglumine (an SCD1 inhibitor) and a selective PPARα agonist significantly reduced fibrotic burden while preserving cardiac muscle integrity and metabolic function in inflammatory human cardiac organoids. This discovery supports the development of Aramchol for cardiac fibrosis and highlights the potential of advanced AI and human organoid models in drug development.

This article compares two healthcare ETFs, State Street Health Care Select Sector SPDR ETF (XLV) and Invesco S&P 500 Equal Weight Health Care ETF (RSPH), highlighting their contrasting investment strategies, costs, and performance. XLV, a market-cap-weighted fund, offers a lower expense ratio, higher dividend yield, and better historical returns. RSPH, an equal-weight fund, provides broader diversification by giving equal impact to all its holdings, regardless of company size.

VeriSign held its annual general meeting where shareholders rejected a proposal for an independent board chairman. Concurrently, the company reported stronger Q1 2026 results and raised its full-year 2026 revenue and operating income guidance. These developments are leading investors to evaluate VeriSign's governance alongside its growth prospects, focusing on its ability to maintain high margins and grow its core .com and .net domain franchise.

Natixis Advisors LLC increased its stake in The Boeing Company by 8.8% in Q4, acquiring an additional 138,924 shares to a total of 1,726,366 shares valued at $374.8 million. Boeing now constitutes 0.5% of Natixis Advisors' portfolio and is its 26th largest holding. The article highlights positive developments for Boeing, including FAA clearance for 737 MAX production ramps and potential China orders, alongside ongoing challenges like its debt load and execution concerns.

Pincus Capital Management LP initiated a new position in Blackstone Inc. during the fourth quarter, acquiring 25,550 shares valued at approximately $3.94 million, making it their 10th-largest holding. This investment comes as Blackstone recently beat Q1 earnings expectations and saw significant insider buying. Analysts currently rate Blackstone as a consensus Hold with an average target price of $151.05.

Natixis Advisors LLC significantly increased its stake in Netflix, Inc. (NASDAQ:NFLX) by 797.3% in the fourth quarter, now holding nearly 5 million shares worth approximately $467.9 million. Other major institutional investors also added to their Netflix holdings, with institutional ownership of the company's stock reaching 80.93%. The company reported strong Q4 earnings, beating analyst estimates for both EPS and revenue, and analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $114.82.